Centenary Institute
Centenary Institute is an independent nonprofit medical research institute in Sydney, Australia, conducting translational research across cancer, cardiovascular, infectious, rare, and age-related diseases through five research centres, affiliated with the University of Sydney and Sydney Local Health District.
- Company typePrivate
- Founded1980
- HeadquartersSydney, Australia
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Centenary Institute does
Centenary Institute (legally Centenary Institute of Cancer Medicine and Cell Biology) is an independent, nonprofit medical research institute headquartered at Royal Prince Alfred Hospital in Camperdown, Sydney, Australia. Established around 1980, the institute operates across five research centres: Biomedical AI, Cancer Innovations, Cardiovascular Research, Infection & Immunity, and Rare Diseases & Gene Therapy. Research spans cancer (melanoma, breast, liver, lung, AML), cardiovascular disease, infectious diseases (particularly tuberculosis and COVID-19), rare diseases, liver disease, diabetes, respiratory diseases, and age-related conditions. The institute is formally affiliated with the University of Sydney and Sydney Local Health District, enabling direct clinical translation through co-location with hospital infrastructure and partnerships with organisations such as Chris O'Brien Lifehouse, Garvan Institute, and NSW Health Pathology.
The institute employs advanced biomedical technologies including a PC3 high-containment facility for live pathogen research, spatial biology platforms developed with the University of Sydney, a multiplex mRNA vaccine platform (commercialised via the Vaxosome spin-out), a mammalian cell protein evolution platform combining directed evolution with machine learning, and the Invasion-Block melanoma screening tool. AI and machine learning are applied within dedicated programmes including protein design and computational biomedicine. Revenue is generated through a diversified mix of competitive government grants (NHMRC, MRFF, ARC, NSW Health, Cancer Australia), philanthropic donations under Deductible Gift Recipient status, industry partnerships with pharmaceutical and biotech firms, financial partnerships with charitable foundations such as Snow Medical Research Foundation ($15.5M) and Breakthrough T1D, and commercialisation/licensing income from spin-out companies. The institute does not sell commercial products and operates on a grant-funded, nonprofit model with no publicly disclosed revenue or ARR figures.
Centenary Institute firmographics
Firmographics- Name
- Centenary Institute
- Legal name
- Centenary Institute of Cancer Medicine and Cell Biology
- Website
- https://centenary.org.au
- Company type
- Private
- Founded year
- 1980
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Centenary Institute is an independent nonprofit medical research institute in Sydney, Australia, conducting translational research across cancer, cardiovascular, infectious, rare, and age-related diseases through five research centres, affiliated with the University of Sydney and Sydney Local Health District.
- Ownership category
- akta.pro rank
Centenary Institute industry classification
Industry- Product category
- Medical Research
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)
- akta.pro primary industry
- Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)
- akta.pro secondary industry
- Health & Biomedical Research Universities (Academic Medical Center–Affiliated) (EDAHABAC)
Keywords
Where Centenary Institute is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Centenary Institute business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Others
Revenue model
- Government Research Grants: Competitive funding from Australian government bodies including NHMRC, MRFF (Medical Research Future Fund), NSW Cardiovascular Research Capacity Program, ARC Discovery Projects, and Cancer Australia. These grants support specific research programs and projects across disease areas.
- Donations and Philanthropy: Charitable donations from individuals, supporters, and trusts including workplace giving programs, fundraising events, bequests, and donations in memory. The institute operates with Deductible Gift Recipient (DGR) status enabling tax-deductible donations.
- Commercialisation and Licensing: Revenue from spin-out companies and commercial partnerships arising from research discoveries, such as Vaxosome mRNA vaccine technology. May include licensing royalties from patented discoveries.
- Industry Partnerships and Grants: Funding from pharmaceutical companies, biotech firms, and charitable foundations including Breakthrough T1D, Tour de Cure, Snow Medical Research Foundation ($15.5M), and others for specific research collaborations.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels10 records
Centenary Institute product offering
Product offeringCore offering
Centenary Institute is an independent medical research institute that conducts laboratory and translational research across five research centres (Biomedical AI, Cancer Innovations, Cardiovascular Research, Infection & Immunity, and Rare Diseases & Gene Therapy). It translates basic science discoveries into clinical applications through hospital partnerships, commercialises research via spin-out companies (e.g., Vaxosome), and trains postdoctoral and postgraduate students.
Product overview
Centenary Institute is a world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to complex health challenges. The institute conducts research across five primary centers: Biomedical AI, Cancer Innovations, Cardiovascular Research, Infection & Immunity, and Rare Diseases & Gene Therapy. Rather than offering commercial software products, the institute focuses on biomedical research, training postdoctoral and postgraduate students, hosting symposia and events, and translating discoveries into clinical applications through its commercialization initiatives.
Differentiator
Problem solved
Functional benefit
Products and services
- Biomedical AI Research Research service combining directed evolution of proteins inside mammalian cells with machine learning, enabling therapeutic protein design and regenerative medicine research for collaborating academic and clinical partners.
- Cancer Innovations Research Translational cancer research service covering melanoma, breast cancer, liver cancer, and AML, including liquid biopsy development, VIRMA targeting, and the Invasion-Block drug screening tool for cancer cell spread.
- Cardiovascular Research Research service investigating genetic variants in inherited heart diseases, developing stem cell-based therapeutic approaches, and conducting vascular biology and endothelial cell dysfunction research.
- Infection & Immunity Research Research service covering tuberculosis vaccine and biomarker development, infectious disease research using PC3 containment, liver immunology, and respiratory disease studies including asthma and COPD.
- Rare Diseases & Gene Therapy Research Research service developing gene and stem cell therapies, including islet-cell replacement therapies for type 1 diabetes and engineered cell treatments for conditions such as GvHD.
- Vaxosome Multiplex mRNA Vaccine Technology Spin-out company commercialising proprietary multiplex mRNA vaccine technology that delivers multiple antigen-encoding instructions via lipid nanoparticles in a single vaccine, enabling broader immune protection against pathogens such as tuberculosis.
Quantifiable outcome
- TB vaccine candidates developed including fully synthetic TB vaccine and CysVac2 protein fusion vaccine with lung-resident memory T cell promotion.
- +4 more outcomes
Companies that use Centenary Institute
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Centenary Institute technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Centenary Institute partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered flagship, major and core.
- VaxosomeflagshipSpin-out company co-founded by Centenary Institute and University of Sydney to develop next-generation multiplex mRNA vaccines targeting tuberculosis and other infectious diseases. Based on foundational research from both institutions. Selected for NSW Government RNA Pipeline Grant.
- Sydney Cancer Partnersmajor$900,000 Translational Fellowship funding and collaborative research framework for cancer research translation between research and clinical settings.
- University of SydneycoreFormal affiliation with University of Sydney enabling academic collaboration, student supervision, joint research programs, and technology transfer. Co-founded Vaxosome spin-out company together with Centenary Institute.
- Sydney Local Health DistrictcoreAffiliated health district providing clinical research infrastructure and enabling translation of discoveries through Royal Prince Alfred Hospital and other district facilities.
- Garvan Institute of Medical ResearchmajorResearch collaboration including joint appointments and translational research partnerships in precision oncology and liquid biopsy development.
- Chris O'Brien LifehousemajorClinical collaboration in cancer research including head and neck cancer blood test discovery and metastatic cancer research with shared clinical oversight.
- University of Sydney - Professor Jamie Triccas and Associate Professor Megan SteaincoreCo-founders of Vaxosome alongside Dr Claudio Counoupas, contributing vaccine development expertise to the multiplex mRNA vaccine program.
- Tuberculosis Centre of Research Excellence (TB-CRE)majorCentenary Institute hosted the 2026 TB-CRE Annual Research Symposium. Partnership focuses on TB control across Australia and Asia-Pacific region through collaborative research.
- NSW Health PathologymajorCollaborated on blood test discovery research to identify head and neck cancer patients at higher risk of relapse.
- World Health OrganizationcoreCentenary Institute hosted a World Health Organization Tuberculosis training session, demonstrating international standing in TB research and policy.
- Tianjin Medical UniversitymajorInternational collaboration with researchers from Tianjin Medical University on liver disease research including liver cross-talk and fatty liver disease studies.
- Royal Prince Alfred HospitalcoreCo-located hospital providing clinical research infrastructure and enabling direct translation of laboratory discoveries into clinical practice.
- Australian National UniversitymajorARC-funded protein design project led by Professor Colin Jackson at ANU, with Associate Professor Daniel Hesselson as Partner Investigator, combining directed evolution and machine learning for therapeutic protein development.
- University of Technology Sydney (UTS)majorCOVID-19 research collaboration within the Centenary UTS Centre for Inflammation, combining institutional capabilities for pandemic response and respiratory disease research.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Centenary Institute competitors and assessment
Company assessmentDirect peers
- The Walter and Eliza Hall Institute of Medical Research (WEHI): Australia's largest medical research institute, working across cancer, immunology and infectious diseases with a similar academic-hospital co-location model, directly comparable in mission and scale of operation to Centenary.
- Garvan Institute of Medical Research: Australia-based independent medical research institute with overlapping programs in cancer genomics, immunology, and translational genomics — Centenary already collaborates with Garvan on precision oncology and liquid biopsy, making it the closest direct peer.
- QIMR Berghofer Medical Research Institute: Queensland-based medical research institute with parallel programs in infectious disease, immunology and cancer genetics, and a comparable funding model of grants, philanthropy, and commercialisation.
- Children's Medical Research Institute: Sydney-based independent medical research institute focused on gene therapy and rare diseases, a direct thematic peer to Centenary's Centre for Rare Diseases & Gene Therapy.
- Baker Heart and Diabetes Institute: Independent Australian medical research institute specialising in cardiovascular and metabolic disease, a direct thematic peer to Centenary's Centre for Cardiovascular Research.
- Harry Perkins Institute of Medical Research: Perth-based medical research institute focused on cancer and chronic diseases with embedded hospital research infrastructure, a similar independent nonprofit research model to Centenary.
- Doherty Institute: University of Melbourne-affiliated institute for infection and immunity, directly comparable in infectious-disease and immunology research areas and in clinical-translation integration.
- South Australian Health and Medical Research Institute (SAHMRI): Independent medical research institute in Adelaide with similar disease-area breadth (cancer, cardiovascular, infectious disease) and university-health district affiliations analogous to Centenary's governance.
Emerging players
- Wellcome Sanger Institute: UK-based genomics and biomedical research institute whose postdoctoral training alumni (Dr Tiffen) lead Centenary programs — comparable as a model of research-intensive, technology-enabled biomedical institute with commercial spin-out pipelines.
Broad incumbents
- Peter MacCallum Cancer Centre: Australia's largest dedicated cancer hospital and research centre, with deeper oncology focus than Centenary but overlapping expertise in melanoma, breast and pancreatic cancer research and translational pipelines.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Centenary Institute social profiles
Digital presenceCentenary Institute financial estimates
Financial estimateRevenue estimate
Valuation estimate
Centenary Institute leadership team
Management profileNumber of profiles
Profiles8 records
Centenary Institute funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Centenary Institute M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Centenary Institute
What does Centenary Institute do?
Centenary Institute is an independent medical research institute that conducts laboratory and translational research across five research centres (Biomedical AI, Cancer Innovations, Cardiovascular Research, Infection & Immunity, and Rare Diseases & Gene Therapy). It translates basic science discoveries into clinical applications through hospital partnerships, commercialises research via spin-out companies (e.g., Vaxosome), and trains postdoctoral and postgraduate students.
Is Centenary Institute a public or private company?
Centenary Institute is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Centenary Institute founded?
Centenary Institute was founded in 1980. It employs 101 to 250 people.
Where is Centenary Institute based?
Centenary Institute is headquartered in Sydney, Australia, in the Oceania region.
How does Centenary Institute make money?
Four revenue lines are on record. Government Research Grants are the primary driver. The others are donations and Philanthropy, commercialisation and Licensing and industry Partnerships and Grants.
Who are Centenary Institute's main competitors?
Direct peers on record are The Walter and Eliza Hall Institute of Medical Research (WEHI), Garvan Institute of Medical Research, QIMR Berghofer Medical Research Institute, Children's Medical Research Institute, Baker Heart and Diabetes Institute, Harry Perkins Institute of Medical Research, Doherty Institute and South Australian Health and Medical Research Institute (SAHMRI). Wellcome Sanger Institute is listed as an emerging player. Peter MacCallum Cancer Centre is listed as a broad incumbent.
Does Centenary Institute have an API?
No public API is recorded for Centenary Institute.
What industry is Centenary Institute in?
Centenary Institute's product category is Medical Research. Its primary akta.pro industry code is EDAHAGAI, Biomedical Sciences & Medical Research Institutes (University-Based), with a secondary code of EDAHABAC, Health & Biomedical Research Universities (Academic Medical Center–Affiliated). Its NAICS code is 54171 and its SIC code is 8731.